Skip to main content
Erschienen in: Medical Oncology 2/2017

01.02.2017 | Short Communication

Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report

verfasst von: Valeria Romeo, Massimiliano D’Aiuto, Giuseppe Frasci, Massimo Imbriaco, Emanuele Nicolai

Erschienen in: Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in four patients with locally advanced breast cancer by simultaneous PET/MRI. Four patients with locally advanced breast cancer underwent simultaneous PET/MRI of the breast using a 3 T Biograph mMR before and after neo-adjuvant chemotherapy (two patients were treated with hormone-therapy and two patients were treated with cytotoxic chemotherapy). Morpho-structural tumoral features and tumor size were assessed; area value, metabolic (SUV and MTV) and functional (ADC, K trans, V e, k ep and iAUC) data were obtained by positioning regions of interest. A comparison of all parameters between the pre- and post-treatment PET/MRI examinations and between the two different therapeutic schedules was assessed. In patients treated with cytotoxic chemotherapy and classified as PR, there was a significant reduction of post-treatment morphological, metabolic and functional parameters. In a patient treated with hormone therapy, classified as SD, there was an increase of all post-treatment perfusion parameters, a substantially stable ADC value and a poor reduction of lesion size and of maximum SUV (SUVmax) values; the last patient, treated with hormone therapy and classified as PR, showed a significant reduction of lesion size and SUVmax values with a reduction of perfusion parameters and substantially stable ADC values. Multiparametric evaluation with simultaneous PET/MRI could be a useful tool to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in patients with breast cancer. Future studies in a larger cohort of patients are warranted to confirm the results of this preliminary study.
Literatur
1.
Zurück zum Zitat Rosenkrantz AB, Friedman K, Chandarana H, et al. Current status of hybrid PET/MRI in oncologic imaging. AJR Am J Roentgenol. 2016;206(1):162–72.CrossRefPubMed Rosenkrantz AB, Friedman K, Chandarana H, et al. Current status of hybrid PET/MRI in oncologic imaging. AJR Am J Roentgenol. 2016;206(1):162–72.CrossRefPubMed
2.
Zurück zum Zitat Ho AM, Kalantari BN. PET/MRI: a new frontier in breast cancer imaging. Breast J. 2016;22(3):261–3.CrossRefPubMed Ho AM, Kalantari BN. PET/MRI: a new frontier in breast cancer imaging. Breast J. 2016;22(3):261–3.CrossRefPubMed
3.
Zurück zum Zitat Tabouret-Viaud C, Botsikas D, Delattre BM, et al. PET/MR in breast cancer. Semin Nucl Med. 2015;45(4):304–21.CrossRefPubMed Tabouret-Viaud C, Botsikas D, Delattre BM, et al. PET/MR in breast cancer. Semin Nucl Med. 2015;45(4):304–21.CrossRefPubMed
4.
Zurück zum Zitat Margolis NE, Moy L, Sigmund EE, et al. Assessment of aggressiveness of breast cancer using simultaneous 18F-FDG-PET and DCE-MRI: preliminary observations. Clin Nucl Med. 2016;41(8):e355–61.CrossRefPubMed Margolis NE, Moy L, Sigmund EE, et al. Assessment of aggressiveness of breast cancer using simultaneous 18F-FDG-PET and DCE-MRI: preliminary observations. Clin Nucl Med. 2016;41(8):e355–61.CrossRefPubMed
5.
Zurück zum Zitat Eiber M, Martinez-Möller A, Souvatzoglou M, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38(9):1691–701.CrossRefPubMed Eiber M, Martinez-Möller A, Souvatzoglou M, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38(9):1691–701.CrossRefPubMed
6.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours; Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours; Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
7.
Zurück zum Zitat O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified Guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576–84.CrossRefPubMed O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified Guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576–84.CrossRefPubMed
8.
Zurück zum Zitat Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17(2):357–67.CrossRefPubMed Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991;17(2):357–67.CrossRefPubMed
9.
Zurück zum Zitat Tateishi Y, Miyake M, Nagaoka T, et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging—prospective assessment. Radiology. 2012;263(1):53–63.CrossRefPubMed Tateishi Y, Miyake M, Nagaoka T, et al. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging—prospective assessment. Radiology. 2012;263(1):53–63.CrossRefPubMed
10.
Zurück zum Zitat Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27(7):683–7.CrossRefPubMed Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27(7):683–7.CrossRefPubMed
11.
Zurück zum Zitat Xu QG, Xian JF. Role of quantitative magnetic resonance imaging parameters in the evalution of treatment response in malignant tumors. Chin Med J. 2015;128(8):1128–33.CrossRefPubMedPubMedCentral Xu QG, Xian JF. Role of quantitative magnetic resonance imaging parameters in the evalution of treatment response in malignant tumors. Chin Med J. 2015;128(8):1128–33.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Yankeelov TE, Lepage M, Chakravarthy A. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer. Magn Reson Imaging. 2007;25(1):1–13.CrossRefPubMed Yankeelov TE, Lepage M, Chakravarthy A. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer. Magn Reson Imaging. 2007;25(1):1–13.CrossRefPubMed
Metadaten
Titel
Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report
verfasst von
Valeria Romeo
Massimiliano D’Aiuto
Giuseppe Frasci
Massimo Imbriaco
Emanuele Nicolai
Publikationsdatum
01.02.2017
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0876-z

Weitere Artikel der Ausgabe 2/2017

Medical Oncology 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.